![Anne Prener](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anne Prener
Direktor/Vorstandsmitglied bei
KEROS THERAPEUTICS, INC.
Vermögen: 147 510 $ am 30.06.2026
Profil
Dr. Anne Prener is an Independent Director at Inventiva SA. She is on the Board of Directors at Keros Therapeutics, Inc., Inventiva SA, Xspray Pharma AB and Cellinta Ltd. Dr. Prener was previously employed as an Independent Director by Galecto, Inc., a Venture Partner by SV Health Investors LLP, a President, Chief Executive Officer & Director by Imbria Pharmaceuticals, Inc., an Independent Director by Kaleido Biosciences, Inc., an Independent Director by VL26, INC., a Chief Executive Officer by Syncona Ltd., a Chief Executive Officer & Director by Freeline Therapeutics Ltd., a Chief Executive Officer by Gyroscope Therapeutics Ltd., a Vice President-Clinical Research Hematology by Baxalta, Inc., a SVP-Hemophilia Research & Development Portfolio by Novo Nordisk A/S, and a Council/Board member by Novo Nordisk (Private Equity).
She also served on the board at Renovacor Holdings, Inc. She received her graduate degree from the University of Copenhagen and a doctorate degree from the University of Copenhagen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.07.2026 | 13’786 ( 0.07% ) | 147 510 $ | 30.06.2026 | |
| 18.06.2025 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Anne Prener
| Unternehmen | Position | Beginn |
|---|---|---|
| XSPRAY PHARMA AB | Direktor/Vorstandsmitglied | 01.01.2025 |
| KEROS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.07.2026 |
| INVENTIVA | Direktor/Vorstandsmitglied | 30.06.2026 |
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Functions as an alternative investment manager for healthcare industry | Direktor/Vorstandsmitglied | 27.03.2020 |
Ehemalige bekannte Positionen von Anne Prener
| Unternehmen | Position | Ende |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.11.2025 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors invests in companies located across the Globe. The firm focuses on biotechnology, pharmaceuticals, medical devices & instruments and healthcare services sectors. It provides financing for seed, early, growth stage and buyout capital requirements. | Private Equity Investor | 01.10.2024 |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Vorstandsvorsitzender | 01.09.2024 |
| RUBIUS THERAPEUTICS | Direktor/Vorstandsmitglied | 12.07.2022 |
| KALEIDO BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 01.04.2022 |
Ausbildung von Anne Prener
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
70
Beziehungen ersten Grades
17
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 17 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors invests in companies located across the Globe. The firm focuses on biotechnology, pharmaceuticals, medical devices & instruments and healthcare services sectors. It provides financing for seed, early, growth stage and buyout capital requirements. | Finance |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novo Nordisk (Private Equity)
 Novo Nordisk (Private Equity) Investment ManagersFinance NNBF invests equity into promising young companies in the health science industry, with a focus on Europe and North America. Their investment strategy focuses on start-ups and later stage biotech firms with a high level of relevance for Novo Nordisk's business model. NNBF focuses on Inflammation, Diabetes, Obesity, Haemostasis, Protein Delivery Systems and Devices, along with Enabling Technologies supporting relevant therapeutic areas. | Finance |
Xspray Pharma AB
 Xspray Pharma AB Pharmaceuticals: MajorHealth Technology Develops and produces particulate materials for the pharmaceutical industry | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
Kaleido Biosciences, Inc.
 Kaleido Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company which develops therapeutic products to systematically shape the micro biome | Health Technology |
Keros Therapeutics, Inc.
 Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Develops transformative gene therapy | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Functions as an alternative investment manager for healthcare industry | Finance |
